drugset / Trial / NCT07374406

To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

NCT07374406

Phase 1 Completed 34 enrolled JW Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

A randomized, open-label, single dose, 2x2 crossover study to evaluate the safety and pharmacokinetic characteristics after administration of Epaminurad in healthy adult volunteers under fasting conditions

Timeline

Start
2026-02-02
Primary completion
2026-02-19
Completion
2026-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Epaminurad Small molecule 9 mg Oral

Indications

No indication recorded.